Clinical Study on Four- versus Two-Hour Hemoadsorption Combined with Hemodialysis for Enhanced Clearance of Protein-Bound Uremic Toxins in Maintenance Hemodialysis Patients
Blood Purification · 16.04.2026 · 1-13
DOI: 10.1159/000551824 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Blood Purification, online erschienen am 16.04.2026. Verfasst von Yang Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Renal Dialysis, Uremic Toxins, Kidney Failure, Chronic, Hemoperfusion. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Introduction
The optimal duration of hemoadsorption durations combined with hemodialysis (HAHD) for maintenance hemodialysis (MHD) patients remains unclear.
Methods
In this randomized controlled trial, we randomized 100 MHD patients to receive either 2-h HAHD group (HD + 2-h HP, n = 50) or 4-h HAHD group (HD + 4-h HP, n = 50) to compare treatment safety and efficacy profiles, with an additional 8 patients enrolled for hemoadsorber saturation assessment. This study received ethical approval from the Institutional Review Board (IRB No. [2024] No. 14).
Results
Results showed that both treatments significantly reduced serum levels of parathyroid hormone and β2-microglobulin, hippuric acid (HA), indole-3-acetic acid (IAA), p-cresyl sulphate (PCS), and kynurenine (KYN) (p < 0.05), with the 4-h HAHD group demonstrating greater clearance of indoxyl sulphate (IS) (p < 0.05) and significantly higher removal rates for HA, IAA, IS, PCS, and KYN compared to 2-h HAHD (p < 0.05). While protein-bound uremic toxins (PBUTs) clearance was similar at 2 h, the 4-h HAHD group achieved superior HA and IAA clearance by 4 h (p < 0.05). Both treatments were well tolerated, with no hematologic abnormalities and comparable adverse event rates.
Conclusion
These findings suggest that 4-h HAHD offers enhanced PBUTs clearance over 2-h HAHD while maintaining a favorable safety profile, supporting its clinical utility in MHD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China.
- Jinan University, Guangzhou, China.
- Department of Nephrology, Henan Provincial People's Clinical Medical School of Zhengzhou University, Zhengzhou, China.
- Department of Nephrology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China, zhtzzu@zzu.edu.cn.
Zitieren
APA
Lu, Y., Zhang, L. J., Yan, G. S., Hu, J. K., Dong, X. X., Fang, Q. Y., Zhu, G. Z., Wan, J. Y., & Zhang, H. T. (2026). Clinical Study on Four- versus Two-Hour Hemoadsorption Combined with Hemodialysis for Enhanced Clearance of Protein-Bound Uremic Toxins in Maintenance Hemodialysis Patients. Blood Purification, 1-13. https://doi.org/10.1159/000551824
Vancouver
Lu Y, Zhang LJ, Yan GS, Hu JK, Dong XX, Fang QY, et al. Clinical Study on Four- versus Two-Hour Hemoadsorption Combined with Hemodialysis for Enhanced Clearance of Protein-Bound Uremic Toxins in Maintenance Hemodialysis Patients. Blood Purification. 2026:1-13. doi:10.1159/000551824
BibTeX
@article{Lu2026,
author = {Lu, Yang and Zhang, Li-Juan and Yan, Guo-Sheng and Hu, Jun-Kai and Dong, Xin-Xin and Fang, Qi-Ying and Zhu, Gui-Zhen and Wan, Jing-Yi and Zhang, Hong-Tao},
title = {Clinical Study on Four- versus Two-Hour Hemoadsorption Combined with Hemodialysis for Enhanced Clearance of Protein-Bound Uremic Toxins in Maintenance Hemodialysis Patients},
journal = {Blood Purification},
year = {2026},
pages = {1--13},
doi = {10.1159/000551824}
}
EUVIMED